Welcome to the Precision Cancer Consortium
Fostering global collaboration to ensure that precision oncology and biomarker-informed, data-driven, equitable patient identification are integrated into routine care and clinical research.
Galicia leads the way in implementing comprehensive genomic profiling as a systemic tool for precision oncology
An agreement signed between SERGAS, and the Precision Cancer Consortium seeks to accelerate the implementation of CGP for all patients with solid tumors from initial diagnosis.
2025, Year in Review
"Our vision is to make precision oncology and CGP the new normal – only together can we achieve this." A message from Precision Cancer Consortium Chair
Insights from Professor Paul Hofman on shaping the future of precision medicine with liquid biopsy
Professor Hofman discussed how liquid biopsy has become an essential component of molecular testing in aNSCLC.
Lean Six Sigma Workflow Optimization Modular Training Available for FREE DOWNLOAD – NEW
Lean Six Sigma is an approach to laboratory workflow optimization to improve diagnostic testing turnaround time and quality.
PCC Wayfinder winners 2025
Celebrating PCC Wayfinders: driving impact to advance precision oncology
Modified genomic testing cost calculator available for FREE download
The PCC, along with IQVIA, have redeveloped the genomic testing cost calculator to incorporate testing costs in USD.
A Collaboration to Address Challenges Associated with Precision Oncology
Challenges that are ecosystem related cannot be solved by one stakeholder of the healthcare system alone. The PCC facilitates collaboration of pharma/biotech companies to address challenges regarding access, awareness, and research and development of comprehensive genomic testing for cancer patients globally.
PCC Strategic Objectives
1
Access
Improve global patient access to precision oncology in both routine care and clinical research
2
Educate
Educate stakeholders and increase awareness on how comprehensive biomarker testing and data analysis can improve patient outcomes
3
Address
Address the challenges of implementing precision oncology in healthcare systems, including biomarker testing and data analysis, to improve equitable treatments and outcomes
PCC Members
The PCC is a group of four pharmaceutical companies with a shared vision, coming together to make biomarker-informed, data-driven patient identification and personalized care standard practice.
The latest from PCC
PCC presents NEW infographic highlighting its impact and vision for precision oncology
The Pathway to Precision Cancer Care: A Strategic and Operational Guide to Enhance Patient Access to...
Welcome to the Precision Cancer Consortium
Driving Global Access to Comprehensive Genomic Profiling for all Patients with Cancer, the Precision...
PCC launches global guide to expand access to CGP and precision cancer care
The Pathway to Precision Cancer Care: A Strategic and Operational Guide to Enhance Patient Access to...
Precision Cancer Consortium strengthens its membership with the addition of industry powerhouse
PCC has bolstered its membership with the addition of Bristol Myers Squibb (BMS).
Expert Insights on Pathology in Clinical Trials
These 10-minute expert-led videos highlight the vital role of pathologists in the success of clinical...
PCC at ASCO 2025
A Scientific Steering Committee, featuring leading oncologist and pathologist key opinion leaders, was...
PCC shortlisted for the Precision Medicine Awards
We’re pleased to share that the Precision Cancer Consortium (PCC) has been shortlisted for the Precision...
2024, Year in Review
"Our vision is to make precision oncology and CGP the new normal – only together can we achieve this."...